Vicore Pharma AB
11
0
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
90%
9 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Role: lead
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Role: lead
Effect of C21 on Forearm Blood Flow
Role: lead
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
Role: lead
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
Role: lead
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
Role: lead
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
Role: lead
Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
Role: lead
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Role: lead
Cold Challenge With C21 in RP
Role: lead
Safety and Efficacy of C21 in Subjects With COVID-19
Role: lead
All 11 trials loaded